TY - JOUR
T1 - SVEP1 is a human coronary artery disease locus that promotes atherosclerosis
AU - Jung, In Hyuk
AU - Elenbaas, Jared S.
AU - Alisio, Arturo
AU - Santana, Katherine
AU - Young, Erica P.
AU - Kang, Chul Joo
AU - Kachroo, Puja
AU - Lavine, Kory J.
AU - Razani, Babak
AU - Mecham, Robert P.
AU - Stitziel, Nathan O.
N1 - Publisher Copyright:
Copyright © 2021 The Authors, some rights reserved.
PY - 2021/3/24
Y1 - 2021/3/24
N2 - A low-frequency variant of sushi, von Willebrand factor type A, EGF, and pentraxin domain-containing protein 1 (SVEP1), an extracellular matrix protein, is associated with risk of coronary disease in humans independent of plasma lipids. Despite a robust statistical association, if and how SVEP1 might contribute to atherosclerosis remained unclear. Here, using Mendelian randomization and complementary mouse models, we provide evidence that SVEP1 promotes atherosclerosis in humans and mice and is expressed by vascular smooth muscle cells (VSMCs) within the atherosclerotic plaque. VSMCs also interact with SVEP1, causing proliferation and dysregulation of key differentiation pathways, including integrin and Notch signaling. Fibroblast growth factor receptor transcription increases in VSMCs interacting with SVEP1 and is further increased by the coronary disease-associated SVEP1 variant p.D2702G. These effects ultimately drive inflammation and promote atherosclerosis. Together, our results suggest that VSMC-derived SVEP1 is a proatherogenic factor and support the concept that pharmacological inhibition of SVEP1 should protect against atherosclerosis in humans.
AB - A low-frequency variant of sushi, von Willebrand factor type A, EGF, and pentraxin domain-containing protein 1 (SVEP1), an extracellular matrix protein, is associated with risk of coronary disease in humans independent of plasma lipids. Despite a robust statistical association, if and how SVEP1 might contribute to atherosclerosis remained unclear. Here, using Mendelian randomization and complementary mouse models, we provide evidence that SVEP1 promotes atherosclerosis in humans and mice and is expressed by vascular smooth muscle cells (VSMCs) within the atherosclerotic plaque. VSMCs also interact with SVEP1, causing proliferation and dysregulation of key differentiation pathways, including integrin and Notch signaling. Fibroblast growth factor receptor transcription increases in VSMCs interacting with SVEP1 and is further increased by the coronary disease-associated SVEP1 variant p.D2702G. These effects ultimately drive inflammation and promote atherosclerosis. Together, our results suggest that VSMC-derived SVEP1 is a proatherogenic factor and support the concept that pharmacological inhibition of SVEP1 should protect against atherosclerosis in humans.
UR - http://www.scopus.com/inward/record.url?scp=85103500604&partnerID=8YFLogxK
U2 - 10.1126/scitranslmed.abe0357
DO - 10.1126/scitranslmed.abe0357
M3 - Article
C2 - 33762433
AN - SCOPUS:85103500604
SN - 1946-6234
VL - 13
JO - Science translational medicine
JF - Science translational medicine
IS - 586
M1 - eabe0357
ER -